Pierre Fabre Laboratories has expanded its global partnership with Atara Biotherapeutics, a T-cell immunotherapy company, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform for EBVALLO (tabelecleucel), a monotherapy registered in the EU for the treatment of relapsed or refractory Epstein–Barr virus positive post–transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy. EBV+ PTLD is a rare, acute, and potentially deadly hematologic m...